For STAT3 pathways, except for directly targeting STAT3 for NPC treatment, targeted inhibition of LMP1, AP1, LncRNA DANCR, and targeted activation of miR-29a, miR-124-3p, and RKIP may become potential treatment strategies for NPC. This evidence concerns the gene STAT3 and nasopharyngeal carcinoma.